112859-74-2

Basic information

• Product Name: (5alpha,16alpha)-16-fluoroandrostan-17-one
• CAS NO: 112859-74-2
• Molecular Formula: C₁₉H₂₉FO
• Molecular Weight: 292.4314
• Mol File: 112859-74-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 372°C at 760 mmHg
• Flash Point: 207.6°C
• Density: 1.07g/cm³
• Vapor Pressure: 9.91E-06mmHg at 25°C
• Refractive Index: 1.514
• CAS DataBase Reference: (5alpha,16alpha)-16-fluoroandrostan-17-one(CAS DataBase Reference)
• NIST Chemistry Reference: (5alpha,16alpha)-16-fluoroandrostan-17-one(112859-74-2)
• EPA Substance Registry System: (5alpha,16alpha)-16-fluoroandrostan-17-one(112859-74-2)

Safety Data

• Hazardous Substances Data: 112859-74-2(Hazardous Substances Data)

Upstream product

• 481-29-8 Epiandrosterone 
• 963-74-6 5alpha-androstan-17-one 

Relevant articles and documents

Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from Trypanosoma cruzi

Chagas disease is a parasitic infection affecting millions of people across Latin America, imposing a dramatic socioeconomic burden. Despite the availability of drugs, nifurtimox and benznidazole, lack of efficacy and incidence of side-effects prompt the identification of novel, efficient, and affordable drug candidates. To address this issue, one strategy could be probing the susceptibility of Trypanosoma parasites toward NADP-dependent enzyme inhibitors. Recently, steroids of the androstane group have been described as highly potent but nonselective inhibitors of parasitic glucose-6-phosphate dehydrogenase (G6PDH). In order to promote selectivity, we have synthesized and evaluated 26 steroid derivatives of epiandrosterone in enzymatic assays, whereby 17 compounds were shown to display moderate to high selectivity for T. cruzi over the human G6PDH. In addition, three compounds were effective in killing intracellular T. cruzi forms infecting rat cardiomyocytes. Altogether, this study provides new SAR data around G6PDH and further supports this target for treating Chagas disease.

Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers

The present invention is related to acute therapeutic uses of dehydroepiandrosterone (DHEA) congeners. These uses include methods for treating or preventing ulcers which comprise administering to a subject either at risk or in need thereof having an ulcer a therapeutic amount of DHEA congener.

Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue

The present invention is related to a method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue. Examples of re-epithelialization in which the invention is particularly suited include, but are not limited to, re-epithelialization of (a) skin following surgical wounds, (b) skin abrasions caused by mechanical trauma, caustic agents or burns, (c) cornea following cataract surgery or corneal transplants, (d) mucosal epithelium (respiratory, gastrointestinal, genitourinary, mammary, oral cavity, ocular tissue, liver and kidney) following infection, nonpathological etiologies or drug therapy, (e) skin following grafting and (f) renal tubule following acute tubular necrosis. Examples of re-endothelialization in which the invention is particularly suited include, but are not limited to, re-endothelialization (or regrowth of endothelium) in blood vessels following angioplasty, and the lysis of fibrin clots or lysis or mechanical disruption of thrombi in coronary arteries. In accordance with the present invention, the time to complete re-epithelialization or re-endothelialization is enhanced or accelerated by administering a dehydroepiandrosterone (DHEA) derivative.